Search Results - "Hasford, Jörg"

Oral insulin immunotherapy in children at risk for type 1 diabetes in a randomised controlled trial by Assfalg, Robin, Knoop, Jan, Hoffman, Kristi L., Pfirrmann, Markus, Zapardiel-Gonzalo, Jose Maria, Hofelich, Anna, Eugster, Anne, Weigelt, Marc, Matzke, Claudia, Reinhardt, Julia, Fuchs, Yannick, Bunk, Melanie, Weiss, Andreas, Hippich, Markus, Halfter, Kathrin, Hauck, Stefanie M., Hasford, Jörg, Petrosino, Joseph F., Achenbach, Peter, Bonifacio, Ezio, Ziegler, Anette-Gabriele

“…Aims/hypothesis Oral administration of antigen can induce immunological tolerance. Insulin is a key autoantigen in childhood type 1 diabetes. Here, oral…”
Get full text

Impact of Variant t(9;22) and Additional Cytogenetic Aberrations at Diagnosis on Prognosis of CML by Leitner, Armin, Saussele, Susanne, Haferlach, Claudia, Schlegelberger, Brigitte, Göhring, Gudrun, Jung-Munkwitz, Susanne, Proetel, Ulrike, Lauseker, Michael, Pfirrmann, Markus, Hasford, Jörg, Hochhaus, Andreas, Hehlmann, Rüdiger

“…Abstract 355 The prognostic relevance of variant t(9;22) and additional cytogenetic aberrations (ACA) at diagnosis of chronic myeloid leukemia (CML) is…”
Get full text

Molecular Response <1% BCR-ABL IS at 12 Months Is Associated with Improved Overall and Progression-Free Survival. the Randomized German CML-Study IV by Müller, Martin C., Hochhaus, Andreas, Lauseker, Michael, Jung-Munkwitz, Susanne, Pfirrmann, Markus, Leitner, Armin, Krause, Stefan W., Pletsch, Nadine, Hanfstein, Benjamin, Schnittger, Susanne, Gratwohl, Alois, Hasford, Jörg, Saussele, Susanne, Hehlmann, Rüdiger

“…Abstract 669 The prognostic relevance of major molecular remission (MMR, <0.1% BCR-ABL according International Scale, IS) for survival has remained uncertain…”
Get full text

Effects of High-Dose Oral Insulin on Immune Responses in Children at High Risk for Type 1 Diabetes: The Pre-POINT Randomized Clinical Trial by Bonifacio, Ezio, Ziegler, Anette-G, Klingensmith, Georgeanna, Schober, Edith, Bingley, Polly J, Rottenkolber, Marietta, Theil, Anke, Eugster, Anne, Puff, Ramona, Peplow, Claudia, Buettner, Florian, Lange, Karin, Hasford, Jörg, Achenbach, Peter

“…IMPORTANCE: Exposing the oral mucosa to antigen may stimulate immune tolerance. It is unknown whether treatment with oral insulin can induce a tolerogenic…”
Get full text

Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV by Hanfstein, Benjamin, Müller, Martin C., Erben, Philipp, Lauseker, Michael, Saussele, Susanne, Proetel, Ulrike, Schnittger, Susanne, Haferlach, Claudia, Kolb, Hans-Jochem, Krause, Stefan W., Nerl, Christoph, Heim, Dominik, Baerlocher, Gabriela M., Schubert, Jörg E.A., Einsele, Hermann, Hänel, Mathias, Dengler, Jolanta, Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Pfirrmann, Markus, Hasford, Jörg, Hofmann, Wolf-Karsten, Hehlmann, Rüdiger, Hochhaus, Andreas

“…Abstract 783▪FN2▪This icon denotes a clinically relevant abstract The advent of second generation tyrosine kinase inhibitors (TKI) in the front line treatment…”
Get full text

Second Line Therapy with Second Generation TKI After Intolerance to Imatinib Based Treatments Showed High Overall Survival in Contrast to Second Line Therapy After Resistance; Results of the Randomized CML Study IV by Saussele, Susanne, Lauseker, Michael, Proetel, Ulrike, Müller, Martin C., Hanfstein, Benjamin, Schreiber, Annette, Nolte, Florian, Baerlocher, Gabriela M., Ehninger, Gerhard, Heim, Dominik, Hossfeld, Dieter K., Krause, Stefan W., Nerl, Christoph, Pralle, Hans, Schubert, Joerg E.A., Einsele, Hermann, Hänel, Matthias, Ho, Anthony D., Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Spiekermann, Karsten, Hofmann, Wolf Karsten, Hasford, Jörg, Pfirrmann, Markus, Hochhaus, Andreas, Hehlmann, Rüdiger

“…Abstract 781▪FN2▪This icon denotes a clinically relevant abstract Data on second line therapy with second generation tyrosine kinase inhibitors (TKI) in CML…”
Get full text

Distinct Characteristics of e13a2 versus e14a2 BCR-ABL Chronic Myeloid Leukemia under Upfront Treatment with Imatinib – an Analysis of the German CML Study IV by Hanfstein, Benjamin, Erben, Philipp, Saussele, Susanne, Lauseker, Michael, Proetel, Ulrike, Haag, Sven, Schnittger, Susanne, Haferlach, Claudia, Kolb, Hans-Jochem, Krause, Stefan W., Nerl, Christoph, Heim, Dominik, Baerlocher, Gabriela M., Schubert, Jörg E.A., Einsele, Hermann, Hänel, Mathias, Dengler, Jolanta, Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Pfirrmann, Markus, Hasford, Jörg, Hofmann, Wolf-Karsten, Hehlmann, Rüdiger, Hochhaus, Andreas, Müller, Martin C.

“…Abstract 3773 The vast majority of chronic myeloid leukemia (CML) patients express a BCR-ABL fusion gene mRNA encoding a 210 kDa tyrosine kinase which is…”
Get full text

Prediction of Molecular Response of Chronic Phase CML Patients by the EUTOS Score: Results of the Randomized CML-Study IV by Saussele, Susanne, Lauseker, Michael, Hoffmann, Verena, Proetel, Ulrike, Hanfstein, Benjamin, Baerlocher, Gabriela M., Heim, Dominik, Ehninger, Gerhard, Hossfeld, Dieter K., Kolb, Hans-Jochem, Krause, Stefan W., Nerl, Christoph, Pralle, Hans, Schubert, Joerg E.A., Einsele, Hermann, Hänel, Matthias, Ho, Anthony D., Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Spiekermann, Karsten, Schnittger, Susanne, Pfirrmann, Markus, Hochhaus, Andreas, Hasford, Jörg, Hehlmann, Rüdiger, Müller, Martin C

“…Abstract 3762 The EUTOS Score was developed and validated as a prognostic tool for the achievement of complete cytogenetic response (CCR) at 18 months for…”
Get full text

Time-Related Interpretation of Molecular Response Levels According to Long Term Overall and Progression-Free Survival of CML Patients on First-Line Imatinib Treatment by Müller, Martin C., Hanfstein, Benjamin, Lauseker, Michael, Erben, Philipp, Proetel, Ulrike, Schnittger, Susanne, Kolb, Hans-Jochem, Krause, Stefan W., Nerl, Christoph, Heim, Dominik, Baerlocher, Gabriela M., Schubert, Joerg E.A., Einsele, Hermann, Hänel, Matthias, Dengler, Jolanta, Falge, Christiane, Kanz, Lothar, Neubauer, Andreas, Kneba, Michael, Stegelmann, Frank, Pfreundschuh, Michael, Waller, Cornelius F., Pfirrmann, Markus, Hasford, Jörg, Hofmann, Wolf-Karsten, Hehlmann, Rüdiger, Saussele, Susanne, Hochhaus, Andreas

“…Abstract 1681 The prognostic impact of different levels of molecular remission (BCR-ABL transcript expression according to International Scale, IS) at various…”
Get full text

Pretreatment Expression Levels of MDR1 and OCT-1 Predict Response to First Line Imatinib Treatment In Chronic Phase CML Patients by Erben, Philipp, Hanfstein, Benjamin, Munjal, Umang, Daikeler, Hannah, Agrawal, Mridul, Popa, Juliana, Nowak, Daniel, Leitner, Armin, Hossfeld, Dieter K, Kolb, Hans J, Krause, Stefan W, Nerl, Christoph, Pralle, Hans, Heim, Dominik, Baerlocher, Gabriela M, Hasford, Jörg, Heimpel, Hermann, Saussele, Susanne, Hofmann, Wolf-Karsten, Hehlmann, Rüdiger, Hochhaus, Andreas, Mueller, Martin C

“…Abstract 671 The goal of imatinib therapy in newly diagnosed CML patients is the rapid achievement of cytogenetic and molecular responses. However, suboptimal…”
Get full text

Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV by Hehlmann, Rüdiger, Jung-Munkwitz, Susanne, Lauseker, Michael, Müller, Martin C., Leitner, Armin, Pletsch, Nadine, Proetel, Ulrike, Gratwohl, Alois, Ehninger, Gerhard, Hossfeld, Dieter K., Nerl, Christoph, Pralle, Hans, Heim, Dominik, Baerlocher, Gabriela M., Balleisen, Leopold, Einsele, Hermann, Falge, Christiane, Ho, Anthony D., Hänel, Matthias, Pfreundschuh, Michael, Kanz, Lothar, Stegelmann, Frank, Köhne, Claus-Henning, Kremers, Stephan, Spiekermann, Karsten, Koschmieder, Steffen, Waller, Cornelius F., Bentz, Martin, Krause, Stefan W., Hanfstein, Benjamin, Schnittger, Susanne, Pfirrmann, Markus, Hasford, Jörg, Hochhaus, Andreas, Saussele, Susanne

“…Abstract 357 Treatment of CML with imatinib of 400 mg can be unsatisfactory. Treatment optimization is warranted. The German CML-Study group has therefore…”
Get full text

Therapy with Imatinib In Elderly CML Patients (>65years): Results of the German CML-Study IV by Saussele, Susanne, Pletsch, Nadine, Lauseker, Michael, Leitner, Armin, Jung-Munkwitz, Susanne, Proetel, Ulrike, Müller, Martin C., Haferlach, Claudia, Schlegelberger, Brigitte, Ehninger, Gerhard, Hossfeld, Dieter K., Krause, Stefan W., Nerl, Christoph, Pralle, Hans, Heim, Dominik, Baerlocher, Gabriela M., Balleisen, Leopold, Einsele, Hermann, Ho, Anthony D., Falge, Christiane, Hänel, Matthias, Pfreundschuh, M., Kanz, Lothar, Stegelmann, Frank, Köhne, Claus-Henning, Kremers, Stephan, Spiekermann, Karsten, Koschmieder, Steffen, Waller, Cornelius F., Bentz, Martin, Pfirrmann, Markus, Hochhaus, Andreas, Hasford, Jörg, Hehlmann, Rüdiger, Group, for The German CML-Study

“…Abstract 3411 Dose of therapy and time to response may be different in the elderly as compared to younger patients with CML. This has been reported previously…”
Get full text

Randomized Comparison of Primary Allogeneic Stem Cell Transplantation and Best Available Drug Treatment in Chronic Myeloid Leukemia by Hehlmann, Rudiger, Pfirrmann, Markus, Hochhaus, Andreas, Müller, Martin C., Hasford, Jörg, Kolb, Hans-Jochem, Heimpel, Hermann, Hossfeld, Dieter K., Gratwohl, Alois

“…Early allogeneic hematopoietic stem cell transplantation (HSCT) has been proposed as primary treatment modality for patients (pts) with chronic myeloid…”
Get full text

Entstehung, Entwicklung und Erfolge des Kompetenznetzes Akute und Chronische Leukämien (KNL) by Kossak-Roth, Ute, Saußele, Susanne, Aul, Carlo, Büchner, Thomas, Döhner, Hartmut, Dugas, Martin, Ehninger, Gerhard, Ganser, Arnold, Giagounidis, Aristoteles, Gökbuget, Nicola, Griesshammer, Martin, Hasford, Jörg, Heuser, Michael, Hiddemann, Wolfgang, Hochhaus, Andreas, Hoelzer, Dieter, Niederwieser, Dietger, Reiter, Andreas, Röllig, Christoph, Hehlmann, Rüdiger

“…Zusammenfassung Im Jahr 1997 wurde durch den Zusammenschluss der führenden Leukämie-Studiengruppen in Deutschland das Kompetenznetz Akute und Chronische…”
Get full text

Allogeneic Transplantation from an HLA-Matched Family Donor in First Complete Remission of Acute Myeloid Leukemia Had an Adverse Impact on Quality of Life in Patients Followed for at Least Five Years after Treatment: A Survey of the German AML Intergroup on 525 Patients by Messerer, Dorle, Engel, Jutta, Hasford, Jörg, Schaich, Markus, Soucek, Silke, Ehninger, Gerhard, Sauerland, Christina, Büchner, Thomas, Niederwieser, Dietger W., Krahl, Rainer, Krauter, Jürgen, Schäfer, Irina, Ganser, Arnold, Schleich, Claire, Döhner, Hartmut, Schlenk, Richard F.

“…The impact of allogeneic blood stem cell transplantation (Allo-SCT) in comparison to conventional chemotherapy (CCT) in AML on quality of life remains unclear…”
Get full text

Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias by Kossak-Roth, Ute, Saußele, Susanne, Aul, Carlo, Büchner, Thomas, Döhner, Hartmut, Dugas, Martin, Ehninger, Gerhard, Ganser, Arnold, Giagounidis, Aristoteles, Gökbuget, Nicola, Griesshammer, Martin, Hasford, Jörg, Heuser, Michael, Hiddemann, Wolfgang, Hochhaus, Andreas, Hoelzer, Dieter, Niederwieser, Dietger, Reiter, Andreas, Röllig, Christoph, Hehlmann, Rüdiger

“…The Competence Network "Acute and Chronic Leukemias" was founded in 1997 by the consolidation of the leading leukemia study groups in Germany. Key results are…”
Get full text

Response: Drug treatment and allografting as first-line therapy in young patients with CML by Hehlmann, Rüdiger, Gratwohl, Alois, Pfirrmann, Markus, Hasford, Jörg, Hochhaus, Andreas, Hossfeld, Dieter K., Heimpel, Hermann

Get full text

Identification of Adverse Drug Events by Stausberg, Jürgen, Hasford, Jörg

Get full text

The European LeukemiaNet: achievements and perspectives by HEHLMANN, Rüdiger, GRIMWADE, David, BÜCHNER, Thomas, BURNETT, Alan, CROSS, Nicolas C. F, DE WITTE, Theo J. M, DÖHNER, Hartmut, DOMBRET, Hervé, EINSELE, Hermann, ENGELICH, Georg, FOA, Robin, FONATSCH, Christa, SIMONSSON, Bengt, GÖKBUGET, Nicola, GLUCKMAN, Elaine, GRATWOHL, Alois, GUILHOT, Francois, HAFERLACH, Claudia, HAFERLACH, Thorsten, HALLEK, Michael, HASFORD, Jörg, HOCHHAUS, Andreas, HOELZER, Dieter, APPERLEY, Jane, KILADJIAN, Jean-Jaques, LABAR, Boris, LJUNGMAN, Per, MANSMANN, Ulrich, NIEDERWIESER, Dietger, OSSENKOPPELE, Gert, RIBERA, Jose M, RIDER, Harald, SERVE, Hubert, SCHROTZ-KING, Petra, BACCARANI, Michele, SANZ, Miguel A, SAUSSELE, Susanne, BARBUI, Tiziano, BAROSI, Giovanni, BASSAN, Renato, BENE, Marie C, BERGER, Ute

“…The only way to cure leukemia is by cooperative research. To optimize research, the European LeukemiaNet integrates 105 national leukemia trial groups and…”
Get full text

Erratum zu: Arzneimittelprüfung an nicht einwilligungsfähigen Erwachsenen: Kritische Bewertung der neuen gesetzlichen Regelung durch medizinische Ethikkommissionen in Deutschland by Götz, Sophie-Charlotte, Marckmann, Georg, Hasford, Joerg, Jox, Ralf J.

“…Erratum zu: Bundesgesundheitsbl 2019 https://link.springer.com/article/10.1007/s00103-019-03058-x In der Originalpublikation des Artikels ist ein Fehler in der…”
Get full text